Expanding the therapeutic horizon for physicians

Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology, peripheral and critical care procedures. We aim to improve patients’ lives through pioneering medical technology that pushes forward the boundaries of innovation.

Biosensors’ success in the Cardiology market has allowed us to develop an extensive portfolio of cardiac stents.

With the BioMatrix™ family of drug-eluting stents, the Axxess™ self-expanding bifurcation stent, and our new BioFreedom™ drug-coated polymer-free stent that delivers an effective anti-restenotic therapy with BA9™ and may shorten the required DAPT regime, we provide workhorse stent platforms for a broad range of coronary lesions.

Through our high quality medical devices, we are committed to continue investing in and developing pioneering medical technologies that will expand the therapeutic horizon for physicians and further benefit our patients.

Our Endovascular product portfolio offers interventional devices to treat peripheral arterial disease; offering stenting and balloon solutions for Superficial Femoral Artery and Below the Knee interventions.
Drug-eluting peripheral stent system for below the knee interventions

Biosensors has received CE Mark approval for the use of BioMatrix Flex in below the Knee (BTK) interventions. This is the latest indication for the BioMatrix family of drug-eluting stents (DES), which have become a popular choice of workhorse in coronary artery disease and will now join Biosensors’ growing portfolio of interventional devices for the treatment of peripheral arterial disease.

BioMatrix Flex BTK features the unique combination of abluminal biodegradable polymer coating, Biolimus A9™ (BA9™) a semi-synthetic sirolimus derivative with increased lipophilicity specially developed for stent use and an advanced stent platform which offers improved trackability and flexibility.

The launch of BioMatrix Flex BTK for below the knee indication reinforces Biosensors’ commitment to improving the quality of life for patients with peripheral arterial disease. With world-class technology backed by outstanding clinical trial results in coronary vessels, peripheral interventions will now benefit from the highest coronary standard of stenting.

Paclitaxel-eluting PTA balloon catheters for above and below the knee interventions

BioPath 035 & 014 are drug-eluting balloon dilatation catheters designed for percutaneous transluminal angioplasty (PTA) and have been optimized for the treatment of patients with peripheral arterial disease.

BioPath 035 is intended for peripheral interventions above the knee and BioPath 014 for infra-popliteal interventions below the knee. The paclitaxel-eluting balloons feature a proprietary shellac coating technology which consistently delivers paclitaxel, an anti-restenotic drug during very brief inflation times, while also minimizing washout of the drug during delivery and placement of the drug-eluting balloon.

BioPath balloon catheters offer excellent pushability, trackability and crossability due to a low balloon profile, low tip entry profile and hydrophilic coating on the distal shaft of the catheter.

A 3D mimetic Nitinol stent system for SFA interventions:

BioMimics 3D is a Nitinol stent which incorporates Veryan Medical’s patented 3D helical geometry technology which promotes natural swirling blood flow to elevate wall shear stress, which has been shown to reduce neointimal hyperplasia.

The BioMimics 3D architecture has also been shown to improve the biomechanical performance of the stent when implanted in the femoropopliteal artery, mitigating the risk of stent fracture and vessel kinking.

Data from the Mimics study have confirmed that BioMimics 3D provides a significant improvement in long-term patency compared to a straight Nitinol control stent in patients undergoing femoropopliteal artery intervention. The data indicate a correlation between primary patency and stent curvature. This important, randomized study shows a clear clinical benefit of the BioMimics 3D technology over the current first generation, straight Nitinol stents.

BioMatrix Flex BTK, BioMatrix, Axxess, BioFreedom, BA9 and BioPath are trademarks or registered trademarks of Biosensors International Group, Ltd. Other cited trademarks are the property of their respective owners.

Not available for sale in the United States and certain other countries.

© 2015. Biosensors International Group, Ltd. All rights reserved.

For more information on our products and technology: www.biosensors.com